Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Horvath

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Biological Psychiatry|February 1, 1984
A study of the reliability of reported premorbid adjustment in schizophrenic patientsN E Small, R C Mohs, R Halperin, et al.
Sexually Transmitted Diseases|March 21, 2008
Temporal associations with declining Trichomonas vaginalis diagnosis rates among women in the state of Victoria, Australia, 1947 to 2005John Marrone, Christopher K Fairley, Marian Saville, et al.
Science (New York, N.Y.)|March 29, 1985
Plasma homovanillic acid concentration and the severity of schizophrenic illnessK L Davis, M Davidson, R C Mohs, et al.
Archives of General Psychiatry|May 1, 1984
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responsesM I Levy, B M Davis, R C Mohs, et al.
Psychopharmacology Bulletin|January 1, 1988
Kraepelinian schizophrenia: a subgroup of schizophrenia?R S Keefe, R C Mohs, M Davidson, et al.
Psychiatry Research|July 28, 1995
Lateral ventricular enlargement in schizotypal personality disorderL J Siever, M Rotter, M Losonczy, et al.
The American Journal of Psychiatry|January 1, 1993
CSF homovanillic acid in schizotypal personality disorderL J Siever, F Amin, E F Coccaro, et al.
Archives of General Psychiatry|March 1, 1985
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problemsB M Davis, K L Davis, R C Mohs, et al.
Clinical Hemorheology and Microcirculation|July 24, 2004
Hemorheological disturbances in patients with chronic cerebrovascular diseasesL Szapary, B Horvath, Zs Marton, et al.
Psychopharmacology Bulletin|January 1, 1983
Oral physostigmine in Alzheimer's diseaseK L Davis, R C Mohs, B M Davis, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Biological Psychiatry|February 1, 1984
A study of the reliability of reported premorbid adjustment in schizophrenic patientsN E Small, R C Mohs, R Halperin, et al.
Sexually Transmitted Diseases|March 21, 2008
Temporal associations with declining Trichomonas vaginalis diagnosis rates among women in the state of Victoria, Australia, 1947 to 2005John Marrone, Christopher K Fairley, Marian Saville, et al.
Science (New York, N.Y.)|March 29, 1985
Plasma homovanillic acid concentration and the severity of schizophrenic illnessK L Davis, M Davidson, R C Mohs, et al.
Archives of General Psychiatry|May 1, 1984
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responsesM I Levy, B M Davis, R C Mohs, et al.
Psychopharmacology Bulletin|January 1, 1988
Kraepelinian schizophrenia: a subgroup of schizophrenia?R S Keefe, R C Mohs, M Davidson, et al.
Psychiatry Research|July 28, 1995
Lateral ventricular enlargement in schizotypal personality disorderL J Siever, M Rotter, M Losonczy, et al.
The American Journal of Psychiatry|January 1, 1993
CSF homovanillic acid in schizotypal personality disorderL J Siever, F Amin, E F Coccaro, et al.
Archives of General Psychiatry|March 1, 1985
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problemsB M Davis, K L Davis, R C Mohs, et al.
Clinical Hemorheology and Microcirculation|July 24, 2004
Hemorheological disturbances in patients with chronic cerebrovascular diseasesL Szapary, B Horvath, Zs Marton, et al.
Psychopharmacology Bulletin|January 1, 1983
Oral physostigmine in Alzheimer's diseaseK L Davis, R C Mohs, B M Davis, et al.
Pageof 11